Abstract 21P
Background
The malignant progression of bladder cancer is a key influencing factor for its poor prognosis. In recent years, numerous studies have shown that circular RNA (circRNA) can regulate the expression of genes in multi-levels, which may play a key role in malignant tumors.
Methods
This study applied bioinformatics methods to preliminarily screened the differentially expressed circular RNAs between bladder cancer and corresponding adjacent tissue. Real-time quantitative PCR(RT-qPCR) experiments were performed to identify differentially expressed circular RNAs in cell lines and tissues of bladder cancer. The functional experiments including plate cloning, CCK-8, Edu and xenograft tumor models were implemented to investigate the biological behavior changes of bladder cancer induced by knocking down hsa_circ_0009061 in vitro and in vivo. Bioinformatics methods were applied to predict miRNAs that circular RNA might bind to and the miRNA target genes, and the real-time quantitative PCR, RNA pulldown,dual luciferase reporter experiment and western blot were utilized to explore the mechanism of hsa_circ_0009061 regulating bladder cancer progression.
Results
The bioinformatics analysis and RT-qPCR find that hsa_circ_0009061 was downregulated in cell lines and tissues of bladder cancer. After successfully knocking down hsa_circ_0009061 in bladder tumor cells, functional experiments including plate cloning, Edu and CCK-8 revealed that silencing hsa_circ_0009061 could promote the malignant proliferation of bladder tumor cell lines in vitro. Xenograft tumor modelalso verified that silencing hsa_circ_0009061 could promote tumor formation in vivo. Mechanistic studies have shown that hsa_circ_0009061 can act as a competitive endogenous RNA to bind to hsa-miR-889-3p and regulate the expression of CPEB3, resulting in the malignant progression of bladder cancer.
Conclusions
This study found that hsa_circ_0009061 was downregulated in cell lines and tumor specimens of bladder cancer and could affect the progression of bladder cancer. Mechanistically, hsa_circ_0009061 can bind to hsa-miR-889-3p to regulate the expression of CPEB3, suggesting that hsa_circ_0009061 may be a new treatment option for bladder cancer.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract